We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Convatec Group Plc | LSE:CTEC | London | Ordinary Share | GB00BD3VFW73 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
9.40 | 3.77% | 258.80 | 259.20 | 259.60 | 260.80 | 251.80 | 252.60 | 5,611,692 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 2.14B | 130.3M | 0.0636 | 40.79 | 5.32B |
TIDMCTEC
RNS Number : 6102G
ConvaTec Group PLC
30 March 2022
Publication of Annual Report and Accounts 2021
and Notice of Meeting
READING, UNITED KINGDOM (30 March 2022) - ConvaTec Group Plc ("ConvaTec" or the "Group"), a global medical products and technologies company, today announces that the following documents are now available on its website at www.convatecgroup.com .
- Annual Report and Accounts 2021 - Notice of Annual General Meeting - Form of Proxy
In compliance with Listing Rule 9.6.1, copies of the Annual Report and Accounts 2021, Notice of Annual General Meeting and Form of Proxy, will be submitted to the National Storage Mechanism and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Printed copies of these documents will be sent to shareholders who have requested hard copies in due course.
Enquiries
Analysts and Investors
Kate Postans, VP Investor Relations, ConvaTec +44 (0)782 644 7807
ir@convatec.com
Media
Buchanan: Charles Ryland / Chris Lane +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACSKZGFFGGNGZZM
(END) Dow Jones Newswires
March 30, 2022 07:00 ET (11:00 GMT)
1 Year Convatec Chart |
1 Month Convatec Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions